Mycophenolic acid
Myfortic (mycophenolic acid) is a small molecule pharmaceutical. Mycophenolic acid was first approved as Myfortic on 2004-02-27. It is used to treat graft vs host disease and psoriasis in the USA. The pharmaceutical is active against inosine-5'-monophosphate dehydrogenase 2 and inosine-5'-monophosphate dehydrogenase 1.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Myfortic (generic drugs available since 2012-08-21)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mycophenolic sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MYFORTIC | Novartis | N-050791 RX | 2004-02-27 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| mycophenolic acid | ANDA | 2023-05-23 |
| myfortic | New Drug Application | 2021-01-28 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| graft vs host disease | — | D006086 | D89.81 |
| psoriasis | EFO_0000676 | D011565 | L40 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J7518 | Mycophenolic acid, oral, 180 mg |
Clinical
Clinical Trials
508 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 146 | 1 | — | 4 | 1 | 152 | ||
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 5 | 12 | 5 | 1 | — | 19 |
| Cataract | D002386 | EFO_0001059 | H26.9 | 1 | — | 1 | 9 | 2 | 13 |
| Infections | D007239 | EFO_0000544 | 5 | 1 | 3 | 1 | 1 | 11 | |
| Endophthalmitis | D009877 | 2 | 5 | 3 | 4 | — | 11 | ||
| Pneumonia | D011014 | EFO_0003106 | J18 | — | 2 | 5 | 2 | 1 | 10 |
| Bacterial infections | D001424 | A49 | 3 | — | 1 | 4 | 1 | 9 | |
| Bacterial conjunctivitis | D003234 | EFO_1000829 | H10.0 | — | 1 | 4 | 3 | — | 8 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 4 | — | 2 | 1 | — | 7 |
| Chronic bronchitis | D029481 | J42 | — | — | 2 | 1 | 4 | 7 |
Show 30 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | — | 11 | 8 | — | 2 | 17 |
| Multidrug-resistant tuberculosis | D018088 | EFO_0007381 | — | 7 | 8 | — | — | 9 | |
| Community-acquired infections | D017714 | — | 2 | 3 | — | — | 5 | ||
| Lung diseases | D008171 | EFO_0003818 | J98.4 | 2 | 1 | 2 | — | — | 4 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | 2 | — | — | 4 |
| Extensively drug-resistant tuberculosis | D054908 | — | 4 | 4 | — | — | 4 | ||
| Contraception | D003267 | 1 | 1 | 1 | — | 1 | 4 | ||
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | — | 3 | — | — | 3 |
| Keratitis | D007634 | H16 | — | — | 3 | — | — | 3 | |
| Lymphoma | D008223 | C85.9 | 1 | — | 1 | — | 1 | 3 |
Show 33 more
Indications Phases 2
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 3 | — | — | — | 1 | 4 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 4 | — | — | — | — | 4 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 4 | — | — | — | — | 4 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 4 | — | — | — | — | 4 |
| Asthma | D001249 | EFO_0000270 | J45 | 3 | — | — | — | — | 3 |
| Hepatitis c | D006526 | B19.2 | 3 | — | — | — | — | 3 | |
| Dyslipidemias | D050171 | HP_0003119 | 3 | — | — | — | — | 3 | |
| Hypoglycemia | D007003 | HP_0001943 | E16.2 | 1 | — | — | — | 1 | 2 |
| Cardiovascular abnormalities | D018376 | EFO_0003848 | 1 | — | — | — | 1 | 2 | |
| Hypertension | D006973 | EFO_0000537 | I10 | 2 | — | — | — | — | 2 |
Show 45 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Long qt syndrome | D008133 | HP_0001657 | I45.81 | — | — | — | — | 2 | 2 |
| Pathologic dilatation | D004108 | — | — | — | — | 2 | 2 | ||
| Keratoconus | D007640 | EFO_0004223 | H18.6 | — | — | — | — | 2 | 2 |
| Regeneration | D012038 | — | — | — | — | 2 | 2 | ||
| Peritonitis | D010538 | EFO_0008588 | K65 | — | — | — | — | 2 | 2 |
| Delirium | D003693 | R41.0 | — | — | — | — | 1 | 1 | |
| Mycoplasma pneumonia | D011019 | EFO_0007387 | J15.7 | — | — | — | — | 1 | 1 |
| Appendicitis | D001064 | EFO_0007149 | K37 | — | — | — | — | 1 | 1 |
| Chemical and drug induced liver injury | D056486 | — | — | — | — | 1 | 1 | ||
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | — | — | — | 1 | 1 |
Show 7 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | MYCOPHENOLIC ACID |
| INN | mycophenolic acid |
| Description | Mycophenolic acid is a member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases. It has a role as an antineoplastic agent, an antimicrobial agent, an EC 1.1.1.205 (IMP dehydrogenase) inhibitor, an immunosuppressive agent, a mycotoxin, a Penicillium metabolite, an environmental contaminant, a xenobiotic and an anticoronaviral agent. It is a gamma-lactone, a member of phenols, a monocarboxylic acid and a member of 2-benzofurans. It is functionally related to a hex-4-enoic acid. It is a conjugate acid of a mycophenolate. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)O)C(=O)OC2 |
Target
Agency Approved
IMPDH2
IMPDH2
IMPDH1
IMPDH1
Organism
Homo sapiens
Gene name
IMPDH2
Gene synonyms
IMPD2
NCBI Gene ID
Protein name
inosine-5'-monophosphate dehydrogenase 2
Protein synonyms
epididymis secretory sperm binding protein, IMP (inosine 5'-monophosphate) dehydrogenase 2, IMP (inosine monophosphate) dehydrogenase 2, IMP dehydrogenase II, IMP oxireductase 2, IMPD 2, IMPDH 2, IMPDH-II, inosine 5' phosphate dehydrogenase 2, inosine monophosphate dehydrogenase type II, Inosine-5'-monophosphate dehydrogenase type II
Uniprot ID
Mouse ortholog
Impdh2 (23918)
inosine-5'-monophosphate dehydrogenase 2 (Q91Z11)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Myfortic - Novartis
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 10,682 documents
View more details
Safety
Black-box Warning
Black-box warning for: Mycophenolic acid, Myfortic
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
25,278 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more